Pulmonary macrophage transplantation therapy.

Pulmonary macrophage transplantation therapy.
复制标题

DOI:
10.1038/nature13807
复制
发表时间:
2014-10-23
期刊:
影响因子:
64.8
通讯作者:
Trapnell, Bruce C.
Trapnell, Bruce C.
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Suzuki, Takuji;Arumugam, Paritha;Sakagami, Takuro;Lachmann, Nico;Chalk, Claudia;Sallese, Anthony;Abe, Shuichi;Trapnell, Cole;Carey, Brenna;Moritz, Thomas;Malik, Punam;Lutzko, Carolyn;Wood, Robert E.;Trapnell, Bruce C.

文献摘要

参考文献

被引文献

相似文献

骨髓移植是一种有效的细胞疗法,但需要清髓,这会增加感染风险和死亡率。最近的谱系追踪研究记录了常驻巨噬细胞群独立于血液祖细胞进行自我维持,促使我们考虑器官靶向、细胞特异性治疗。在这里,使用GM-CSF受体-β缺陷(Csf2rb−/−)小鼠,这些小鼠出现与CSF2RA/CSF2RB突变儿童的遗传性肺泡蛋白沉积症(hPAP)相同的骨髓细胞疾病,我们表明,野生型或Csf2rb基因校正巨噬细胞的肺巨噬细胞移植(PMT)无需清髓术,是安全的,耐受性良好,并且一次给药即可纠正肺部疾病、继发性全身表现、疾病相关生物标志物正常化,并预防疾病特异性死亡率。 PMT 衍生的肺泡巨噬细胞和治疗效果一样可持续至少一年。结果确定了健康和疾病中调节肺泡巨噬细胞数量的机制,表明 GM-CSF 是肺泡巨噬细胞表型测定所必需的,并支持将 PMT 转化为 hPAP 儿童的第一个特异性疗法。
Bone marrow transplantation is an effective cell therapy but requires myeloablation, which increases infection-risk and mortality. Recent lineage-tracing studies documenting that resident macrophage populations self-maintain independent of hematologic progenitors prompted us to consider organ-targeted, cell-specific therapy. Here, using GM-CSF receptor-β deficient (Csf2rb−/−) mice that develop a myeloid cell disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA/CSF2RB mutations, we show that pulmonary macrophage transplantation (PMT) of either wild-type or Csf2rb-gene-corrected macrophages without myeloablation was safe, well-tolerated, and that one administration corrected the lung disease, secondary systemic manifestations, normalized disease-related biomarkers, and prevented disease-specific mortality. PMT-derived alveolar macrophages persisted for at least one year as did therapeutic effects. Results identify mechanisms regulating alveolar macrophage population size in health and disease, indicate that GM-CSF is required for phenotypic determination of alveolar macrophages, and support translation of PMT as the first specific therapy for children with hPAP.
DOI: 10.1084/jem.20080759
发表时间: 2008-11-24
期刊: The Journal of experimental medicine
影响因子: --
作者:
Martinez-Moczygemba M;Doan ML;Elidemir O;Fan LL;Cheung SW;Lei JT;Moore JP;Tavana G;Lewis LR;Zhu Y;Muzny DM;Gibbs RA;Huston DP
通讯作者: Huston DP
DOI: 10.1371/journal.pone.0006995
发表时间: 2009-09-10
期刊: PLOS ONE
影响因子: 3.7
作者:
Arumugam, Paritha I.;Urbinati, Fabrizia;Malik, Punam
通讯作者: Malik, Punam
DOI: 10.1038/ni.2419
发表时间: 2012-11
期刊: Nature immunology
影响因子: 30.5
作者:
通讯作者: --
DOI: 10.1084/jem.183.6.2657
发表时间: 1996-06-01
影响因子: 15.3
作者:
Nishinakamura, R;Wiler, R;Murray, R
通讯作者: Murray, R
DOI: 10.1152/ajplung.00216.2003
发表时间: 2003-11-01
影响因子: 4.9
作者:
Bonfield, TL;Raychaudhuri, B;Thomassen, MJ
通讯作者: Thomassen, MJ